Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors
2018 ◽
Vol 117
(4)
◽
pp. 326-331
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7539-7539
2017 ◽
Vol 9
(7)
◽
pp. 1980-1987
◽
Keyword(s):